<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21087" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Endocarditis Antibiotic Regimens</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tackling</surname>
            <given-names>Gary</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lala</surname>
            <given-names>Vasimahmed</given-names>
          </name>
          <aff>Michigan State University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gary Tackling declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vasimahmed Lala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21087.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Infective endocarditis is an uncommon infection with a high mortality rate. It requires prompt identification and carefully selected antibiotic therapy. This activity outlines the general antibiotic principles associated with treating infective endocarditis and highlights the importance of the interprofessional team in caring for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify treatment considerations for patients with infective endocarditis.</p></list-item><list-item><p>Review the classic presentation of infective endocarditis.</p></list-item><list-item><p>Describe the etiology of infective endocarditis.</p></list-item><list-item><p>Outline important interprofessional management considerations for infective endocarditis treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21087&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21087">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21087.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Endocarditis is an uncommon infection occurring every 3 to 7 per 100000 person-years. Yet, it is also the fourth most common life-threatening infection after sepsis, pneumonia, and intraabdominal abscess, with an estimated inpatient mortality rate between 15 to 30%. When endocarditis was first widely studied in the 1960s, streptococcus viridian was the most commonly identified pathogen. However, the epidemiology has shifted, with <italic toggle="yes">Staphylococcus aureus</italic> being the most frequently identified pathogen. While this shift is partially attributable to an increased rate of intravenous drug abuse in North America, the healthcare-associated infection has become increasingly common, representing about 30% of all endocarditis cases.</p>
        <p>The management of endocarditis requires an interprofessional approach by infectious disease, cardiology, and cardiac surgery to manage antimicrobial therapy and assess for possible surgical intervention.<xref ref-type="bibr" rid="article-21087.r1">[1]</xref> Early consultation with cardiothoracic surgery has been shown to improve mortality and is mandatory in patients presenting with complications. Approximately 50% of patients with endocarditis will require some form of surgical intervention.<xref ref-type="bibr" rid="article-21087.r2">[2]</xref>&#x000a0;According to the American Heart Association recommendation, a consult with an infectious disease expert should occur before initiating empiric antibiotic therapy due to the many nuances associated with treating endocarditis. Vegetations contain densely packed bacteria interlocked within a biofilm composed of fibrin and platelets, which creates a mechanical barrier limiting antibiotic penetration. Each antibiotic class has differing pharmacological properties which influence the rate of diffusion, distribution, and ability of the antibiotic to penetrate the vegetation, which ultimately determines the bactericidal efficacy. The duration of therapy for successfully eradicating bacteria has its basis in the bactericidal action of the specific antibiotic, minimal inhibitory concentration, pathogen, vegetation burden, and area of involvement. The duration of treatment can range from 2 to 6 weeks.</p>
        <p>The American Heart Association 2015 Adult Infective Endocarditis guidelines and European Society of Cardiologists 2015 management of infective endocarditis guidelines serve as the basis for the following recommendation.<xref ref-type="bibr" rid="article-21087.r2">[2]</xref><xref ref-type="bibr" rid="article-21087.r3">[3]</xref> The treatment of endocarditis should be pathogen-directed and directed by blood cultures and antibiotic sensitivities. Therefore it is imperative to obtain at least two separate blood cultures (preferably three) from two different venous sites for targeted antibiotic therapy before administering antibiotics. Blood cultures ideally should be repeated every 24 to 48hrs until they are negative. Patients should undergo assessment for clinical response to antibiotics. Most patients become afebrile within 3 to 5 days of appropriate antibiotics.</p>
        <p>In patients who present with an indolent, uncomplicated course, antibiotic therapy can be delayed until cultures and sensitivities are available. However, in patients with a more acute presentation or features of complicated endocarditis, prompt empiric treatment is often required to reduce the risk of complications. The recommendation is for an Infectious disease consultation when selecting empiric antibiotic therapy as various factors influence the choice of empiric antibiotics, including patients characteristics and risk factors, epidemiological factors, recent administration of antibiotics, whether the infection was healthcare-associated, and severity of presentation.</p>
      </sec>
      <sec id="article-21087.s3" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>The presence of a bioprosthetic valve or implantable cardiac device plays a significant influence on antibiotic selection duration of treatment as it portends a more severe infection with higher rates of treatment failure than native valve endocarditis. They also have a higher mortality rate, increased complications rate, and a higher rate of treatment failure than patients with native valve endocarditis, even if infection occurs with the same pathogen. Additionally, patients with a prosthetic valve or implantable cardiac device are at higher risk for developing endocarditis. Empiric antibiotic therapy for prosthetic valve and health-care-associated endocarditis should be broader and cover MRSA, enterococci, and gram-negative pathogens. Empiric antibiotics should consist of combination bactericidal treatment with vancomycin, gentamicin, and either cefepime or another antipseudomonal carbapenem (imipenem, meropenem, or doripenem). If the patient is found to have <italic toggle="yes">Staphylococcus</italic> and a prosthetic valve, combination antibiotic therapy with rifampin is recommended. Rifampin has been shown to sterilize and should be started three to five days after blood cultures become negative.</p>
        <p>Prosthetic valve endocarditis is more challenging to treat with higher rates of antibiotic failure and increased risk of complications. These patients should receive an early evaluation with a cardiothoracic surgeon as surgery has been shown to improve mortality.<xref ref-type="bibr" rid="article-21087.r4">[4]</xref> Prosthetic valve endocarditis can be subdivided based on the time interval since valve replacement.</p>
        <list list-type="bullet">
          <list-item>
            <p>Early prosthetic valve endocarditis (PVE) occurs within 60 days of valve replacement. It is typically iatrogenic and caused by <italic toggle="yes">S. aureus</italic> or coagulase-negative Staph.</p>
          </list-item>
          <list-item>
            <p>Intermediate PVE occurs between 60 to 365 days of valve replacement, and most common is the result of <italic toggle="yes">Streptococcus</italic> or staph infection.</p>
          </list-item>
          <list-item>
            <p>Late endocarditis occurs one year or longer after valve replacement. It typically results from organisms similar to those found in native valve endocarditis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21087.s4" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>The diagnosis of infective endocarditis is contingent upon positive blood cultures. Persistent bacteremia is typical of this infection. However, 5% to 10% of infections are found to be culture negative. Several factors can influence this, including prior administration of antibiotics before culture, fastidious or hard to cultures infectious organisms such as HACEK organisms or fungal infection, or poor microbiologic technique upon collection and cultures. Administration of antibiotics before culture reduces the ability to accurately culture bacteria by 35% to 40%. The selection of antibiotic therapy in culture-negative patients is very challenging. Withdrawal of antibiotics and repeating blood cultures until an organism is isolated can be a consideration. Serology for a fastidious organism such as <italic toggle="yes">Coxiella</italic>, <italic toggle="yes">Bartonella</italic>, <italic toggle="yes">Brucella</italic>, <italic toggle="yes">Mycoplasma,</italic> or <italic toggle="yes">Aspergillus</italic> can also be an option.</p>
        <p>The prognosis of endocarditis depends upon infecting organism, the presence of complications, echo findings, and patient characteristics such as age or comorbidities. Acute heart failure, staph aureus infection, and penannular complications convey the highest risk of death, and early urgent surgical consultation is strongly recommended.</p>
      </sec>
      <sec id="article-21087.s5" sec-type="Other Issues">
        <title>Other Issues</title>
        <p>Empiric antimicrobial therapy in native valve endocarditis targets the three most common pathogens: staphylococcus, streptococcus, or enterococci.<xref ref-type="bibr" rid="article-21087.r5">[5]</xref> Critically ill patients may require more intensive antibiotic therapy such as ampicillin with gentamicin and flucloxacillin, or oxacillin can be used empirically in severely ill patients with native valve endocarditis or late PVE.<xref ref-type="bibr" rid="article-21087.r6">[6]</xref> Antibiotic therapy should undergo adjustment as gram stain, culture, and susceptibilities become available. Native valve endocarditis treatment typically requires 2 to 6 weeks of antibiotics.</p>
        <list list-type="bullet">
          <list-item>
            <p>Initial antibiotic therapy for critically ill patients before cultures and sensitivities:<xref ref-type="bibr" rid="article-21087.r3">[3]</xref>
<list list-type="bullet"><list-item><p>Ampicillin + gentamicin + flucloxacillin or oxacillin</p></list-item><list-item><p>Vancomycin + gentamicin (if PCN allergic)</p></list-item><list-item><p>Vancomycin + gentamicin + rifampin if early prosthetic valve endocarditis (under one year) or healthcare-associated endocarditis</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>For patients with gram-positive cocci in clusters found on gram stain, monotherapy with empiric vancomycin every 8 to 12 hours dosed to maintain a concentration of 15 to 20 mg/kg is appropriate. When cultures and sensitivities are available, antibiotics coverage should be narrowed. If the patient is found to have methicillin-sensitive endocarditis, then nafcillin or oxacillin dosed up to 12g per day divided dosed every four to six hours. Vancomycin has less effective bactericidal action than penicillin or beta-lactamase-based therapies. As such, it should be limited to patients with severe reactions to PCN or beta-lactamase or patients with MRSA. In patients who have methicillin-resistant staph aureus, monotherapy with vancomycin 30mg/kg or daptomycin 6 to 10mg/kg is the treatment of choice. Historically, combination therapy using a beta-lactam with an aminoglycoside was formerly the treatment of choice. However, aminoglycosides in combination with vancomycin have increased the risk of nephrotoxicity and ototoxicity while providing minimal to no survival benefit. As such, the American Heart Association now discourages concomitant aminoglycoside use with vancomycin for use in MRSA.</p>
        <list list-type="bullet">
          <list-item>
            <p>MSSA
<list list-type="bullet"><list-item><p>Native&#x000a0; 
<list list-type="bullet"><list-item><p>Four to six weeks of oxacillin&#x000a0;</p></list-item><list-item><p>Four to six weeks of cefazolin or cefotaxime is the recommendation for patients with non-anaphylactic PCN allergies.</p></list-item></list>
</p></list-item><list-item><p>PVE
<list list-type="bullet"><list-item><p>Six weeks of oxacillin + 6 weeks of rifampin + 2 weeks gentamicin</p></list-item><list-item><p>Six weeks of cefazolin or cefotaxime + 6 weeks of rifampin + 2 weeks gentamicin if PCN anaphylaxis</p></list-item><list-item><p>Six weeks of vancomycin + 6 weeks of rifampin + 2 weeks gentamicin if PCN anaphylaxis</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>MRSA or PCN/beta-lactam anaphylaxis
<list list-type="bullet"><list-item><p>Four to six weeks of vancomycin or daptomycin</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>For patients found to have streptococcus, determination of penicillin susceptibility is an important consideration. PCN susceptibility in Streptococcus is defined as (MIC less than or equal to 0.125 mg/L) and is associated with cure rates exceeding 95%. Patients with uncomplicated NVE and normal renal function can have a two-week course of Gentamicin and penicillin G or ceftriaxone. Ceftriaxone and gentamicin are both dosed once daily, so this therapy is ideal for outpatient antibiotic therapy. Intermediate PCN susceptibility, defined as (MIC&#x000a0; 0.25 &#x02013; 2 mg/L) requires at least a four-week course of antibiotics with at least two weeks of gentamicin.</p>
        <list list-type="bullet">
          <list-item>
            <p>PCN sensitive Streptococcus (MIC less than or equal to 0.125 mg/L)
<list list-type="bullet"><list-item><p>Native Valve Endocarditis
<list list-type="bullet"><list-item><p>Two weeks of penicillin G or ceftriaxone and gentamicin (only for non-complicated NVE and normal renal function)</p></list-item><list-item><p>Four weeks of penicillin G or ceftriaxone or amoxicillin (ESC only)</p></list-item><list-item><p>Four weeks of vancomycin if PCN allergic and unable to sensitize</p></list-item></list>
</p></list-item><list-item><p>Prosthetic Valve Endocarditis
<list list-type="bullet"><list-item><p>Six weeks of penicillin G or ceftriaxone or amoxicillin for PVE</p></list-item><list-item><p>Six weeks of vancomycin (if PCN allergic and unable to sensitize)</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>PCN resistant Streptococcus (MIC&#x000a0; 0.25 &#x02013; 2 mg/L)&#x000a0;
<list list-type="bullet"><list-item><p>Native Valve Endocarditis 
<list list-type="bullet"><list-item><p>Four weeks of penicillin G or ceftriaxone + 2 weeks of gentamicin</p></list-item><list-item><p>Four weeks of vancomycin +/- gentamicin (ESC) if PCN allergic</p></list-item></list>
</p></list-item><list-item><p>PVE
<list list-type="bullet"><list-item><p>Six weeks of penicillin G or ceftriaxone + 2 weeks of Gentamicin</p></list-item><list-item><p>Six weeks of vancomycin + 2 weeks of gentamicin (ESC) if PCN allergic</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Enterococcus infective endocarditis typically results from Enterococcus faecalis&#x000a0;(95%) or Enterococcus faecium&#x000a0;(3%). Enterococci is difficult to treat as they have several defense mechanisms that allow resistance to a wide range of antibiotics such as aminoglycosides, beta-lactams, and vancomycin. One important factor to consider when treating enterococci is aminoglycoside resistance. High-level aminoglycoside resistance (HLAR) has a MIC greater than 500 mg/L, and aminoglycoside therapy is inappropriate. Successful eradication requires combination synergistic bacteriocidal therapy for at least 4 to 6 weeks. Combination therapy frequently consists of either two cell wall inhibitors or an aminoglycoside with a cell wall inhibitor. The treatment of choice for susceptible enterococcus infection is ceftriaxone and ampicillin for both HLAR and non-HLAR enterococci.</p>
        <list list-type="bullet">
          <list-item>
            <p>Enterococcus
<list list-type="bullet"><list-item><p>Six weeks of ampicillin + ceftriaxone (for both HLAR and nonHLAR)</p></list-item><list-item><p>Four to six weeks of amoxicillin + gentamicin (not for HLAR)</p></list-item><list-item><p>Six weeks of vancomycin + gentamicin (if PCN allergic)</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21087.s6" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Selection of appropriate antibiotic regimens requires an interprofessional team approach involving physicians and nurses (particularly those with specialized infectious disease backgrounds), pharmacists, and primary care physicians. Further, consultation and coordination with an infectious&#x000a0;disease specialist are usually necessary. [Level 5] Empirical antibiotic therapy is recommended if the suspicion of endocarditis is high; once culture results are obtained, the antibiotic selection can target the sensitivity of the organism.</p>
        <p>In general, the nurse practitioner or physician assistant will manage the empirical antibiotic selection and coordinate with the physician regarding antibiotic prophylaxis coverage. The pharmacist will review the selection, allergies, and indications to determine appropriate coverage. If there is a concern, the pharmacist should report back to the clinical team a need for an alternative selection. The medical team will need to monitor the patient for signs of endocarditis development and report back to the team leader as issues develop.</p>
        <p>Management of antibiotic regimens for infective endocarditis is best achieved with an interprofessional team involving physicians, infectious disease experts, specialty-trained nursing staff, and pharmacists all collaborating to manage the cases to an optimal patient outcome.<xref ref-type="bibr" rid="article-21087.r7">[7]</xref><xref ref-type="bibr" rid="article-21087.r8">[8]</xref> [Level 5]</p>
      </sec>
      <sec id="article-21087.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21087&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21087">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21087/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21087">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21087.s8">
        <title>References</title>
        <ref id="article-21087.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chirillo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Scotton</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rocco</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rigoli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Borsatto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pedrocco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Leo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Minniti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Polesel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Olivari</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Impact of a multidisciplinary management strategy on the outcome of patients with native valve infective endocarditis.</article-title>
            <source>Am J Cardiol</source>
            <year>2013</year>
            <month>Oct</month>
            <day>15</day>
            <volume>112</volume>
            <issue>8</issue>
            <fpage>1171</fpage>
            <page-range>1171-6</page-range>
            <pub-id pub-id-type="pmid">23831163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21087.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baddour</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Bayer</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Tleyjeh</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Rybak</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Barsic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lockhart</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Gewitz</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Levison</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Bolger</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Steckelberg</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Baltimore</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Taubert</surname>
                <given-names>KA</given-names>
              </name>
              <collab>American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council</collab>
            </person-group>
            <article-title>Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2015</year>
            <month>Oct</month>
            <day>13</day>
            <volume>132</volume>
            <issue>15</issue>
            <fpage>1435</fpage>
            <page-range>1435-86</page-range>
            <pub-id pub-id-type="pmid">26373316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21087.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Habib</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lancellotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Antunes</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bongiorni</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Casalta</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Del Zotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dulgheru</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>El Khoury</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Erba</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Iung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Miro</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mulder</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Plonska-Gosciniak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roos-Hesselink</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Snygg-Martin</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Thuny</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tornos Mas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vilacosta</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Zamorano</surname>
                <given-names>JL</given-names>
              </name>
              <collab>Task Force per il Trattamento dell'Endocardite Infettiva della Societ&#x000e0; Europea di Cardiologia (ESC)</collab>
            </person-group>
            <article-title>[2015 ESC Guidelines for the management of infective endocarditis. The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)].</article-title>
            <source>G Ital Cardiol (Rome)</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>277</fpage>
            <page-range>277-319</page-range>
            <pub-id pub-id-type="pmid">27093212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21087.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mihos</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Capoulade</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yucel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Picard</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Santana</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Surgical Versus Medical Therapy for Prosthetic Valve Endocarditis: A&#x000a0;Meta-Analysis of 32 Studies.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>103</volume>
            <issue>3</issue>
            <fpage>991</fpage>
            <page-range>991-1004</page-range>
            <pub-id pub-id-type="pmid">28168964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21087.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Athan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Olaison</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Par&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Almirante</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rizzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Naber</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Logar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tattevin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Iarussi</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Selton-Suty</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Casab&#x000e9;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Corey</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Cabell</surname>
                <given-names>CH</given-names>
              </name>
              <collab>International Collaboration on Endocarditis-Prospective Cohort Study Investigators</collab>
            </person-group>
            <article-title>Contemporary clinical profile and outcome of prosthetic valve endocarditis.</article-title>
            <source>JAMA</source>
            <year>2007</year>
            <month>Mar</month>
            <day>28</day>
            <volume>297</volume>
            <issue>12</issue>
            <fpage>1354</fpage>
            <page-range>1354-61</page-range>
            <pub-id pub-id-type="pmid">17392239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21087.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Habib</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lancellotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Antunes</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bongiorni</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Casalta</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Del Zotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dulgheru</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>El Khoury</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Erba</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Iung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Miro</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mulder</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>P&#x00142;o&#x00144;ska-Go&#x0015b;ciniak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roos-Hesselink</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Snygg-Martin</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Thuny</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mas</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Vilacosta</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Zamorano</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>[2015 ESC Guidelines for the management of infective endocarditis].</article-title>
            <source>Kardiol Pol</source>
            <year>2015</year>
            <volume>73</volume>
            <issue>11</issue>
            <fpage>963</fpage>
            <page-range>963-1027</page-range>
            <pub-id pub-id-type="pmid">26726820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21087.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brands</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Abraham-Inpijn</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>[Miscommunication during the treatment of a medically compromised patient].</article-title>
            <source>Ned Tijdschr Tandheelkd</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>118</volume>
            <issue>12</issue>
            <fpage>613</fpage>
            <page-range>613-6</page-range>
            <pub-id pub-id-type="pmid">22292353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21087.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Tackling</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lala</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <chapter-title>Endocarditis Antibiotic Regimens</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31194319</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
